Zanolimumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Zanolimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CD4
Identifiers
CAS Number 652153-01-0 N
ATC code none
ChemSpider none
UNII HG3L8885M0 YesY
KEGG D06356 YesY
Chemical data
Molar mass 147 kg/mol
 NYesY (what is this?)  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]

References[edit]

  1. ^ Genmab initiates Phase II Study with HuMax-CD4 Archived May 16, 2008, at the Wayback Machine.
  2. ^ "Archived copy". Archived from the original on April 11, 2010. Retrieved August 20, 2010. 
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  4. ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
  5. ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011. 


Retrieved from "https://en.wikipedia.org/w/index.php?title=Zanolimumab&oldid=749726292"